COMP <GO>
NNNN vs MRK // PIOTROSKI F-SCORE QUALITY
Anbio Biotechnology (Class A) (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: NNNN 4
— MRK 8
▲ PIOTROSKI F-SCORE QUALITY LEADER: MRK
LAST: $3.36 (-9.68%) • MKT CAP: $535.3M
piotroski-score
5/9
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
piotroski-score
7/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NNNN VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NNNN | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 87.20% | 74.80% | +12.40 | NNNN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 17.00% | 20.70% | -3.70 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 91.5x | 15.3x | +76.20 | MRK | /valuation <GO> |
| Free Cash Flow Yield | -1.26% | 3.42% | -4.68 | MRK | /fcf-yield <GO> |
| Operating Margin | 66.70% | 34.30% | +32.40 | NNNN | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 28.10% | +39.90 | NNNN | /net-margins <GO> |
| Revenue Growth (YoY) | 5.60% | 1.30% | +4.30 | NNNN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 5.19 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 5/9 | 7/9 | -2.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 37.9 | 51.7 | -13.80 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 77.7x | 18.4x | +59.30 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $535.3M | $361.02B | -$360.49B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NNNN REV | MRK REV | NNNN GROSS % | MRK GROSS % | NNNN FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $8.6M | $65.01B | 87.2% | 74.8% | -$6.7M | $12.36B |
| FY 2024 | $8.2M | $64.17B | 71.9% | 76.3% | $2.1M | $18.10B |
| FY 2023 | $6.7M | $60.12B | — | — | $898.4K | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NNNN // BETA —
MRK // BETA 0.92